Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 36.87 -5.32% -2.07
APLS closed down 5.32 percent on Friday, February 21, 2020, on 70 percent of normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Flat Down
Historical APLS trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Medicine Biopharmaceutical Clinical Medicine Organ Systems Macular Degeneration Autoimmune And Inflammatory Diseases Chronic Obstructive Pulmonary Disease Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Treatment Of Chronic Obstructive Pulmonary Disease Complement System Pnh

Is APLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 45.04
52 Week Low 13.8
Average Volume 1,533,674
200-Day Moving Average 28.61
50-Day Moving Average 36.83
20-Day Moving Average 41.69
10-Day Moving Average 41.25
Average True Range 2.02
ADX 28.98
+DI 17.39
-DI 28.25
Chandelier Exit (Long, 3 ATRs ) 38.97
Chandelier Exit (Short, 3 ATRs ) 42.79
Upper Bollinger Band 45.12
Lower Bollinger Band 38.25
Percent B (%b) -0.2
BandWidth 16.48
MACD Line 0.46
MACD Signal Line 1.44
MACD Histogram -0.9853
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.86
Resistance 3 (R3) 41.25 40.32 40.20
Resistance 2 (R2) 40.32 39.30 40.12 39.97
Resistance 1 (R1) 38.59 38.67 38.13 38.20 39.75
Pivot Point 37.66 37.66 37.42 37.46 37.66
Support 1 (S1) 35.93 36.64 35.47 35.54 33.99
Support 2 (S2) 35.00 36.01 34.80 33.77
Support 3 (S3) 33.27 35.00 33.55
Support 4 (S4) 32.88